Antithrombin III in rat hepatocytes

Albumin, Fibrinogen, Prothrombin and Antithrombin III Variations in Blood, Urines and Liver in Rat Nephrotic Syndrome (Heymann Nephritis)

“…Still in the recent past, the localization of the AT 111 synthesis was a subject of controversy because the findings of Lee et al failed to show AT III. :in hepatocytes (22), which contrasted with previous (23) and recent studies (4,5,18,24) demonstrating the likely hepatic synthesis of this protein, that do not exclude other cellular origin for AT III. All these findings, confirmed by our results, authorize the study of variations of the production of these four proteins under experimental conditions by the mean of a quantitative technique of the protein synthesis as the immunocytochemical method we used.…”

“…Rat AT ZZZ and anti AT ZZZserum. Purified rat AT I11 was prepared as described elsewhere (5). AT 111 was used to raise specific antiserum in rabbits and IgG fraction of this antiserum was purified as described by Steinbuch et al to perform immunocytochemistry and studies using electroimmunodiffusion.…”

“…The variations of the blood levels of proteins differ according to several factors, among which their molecular weightlow molecular weight proteins are lost in the urines, but high molecular weight proteins are notand their capacity to modify their syntheses, seem to be the most important ones. Hepatocytes have been proved to be the site of synthesis of albumin (I), prothrombin (2), fibrinogen (3) and antithrombin I11 (AT 111) (4,5). The objectives of this work are to investigate the variations in Correspondence to: Dr. Robert Girot, Laboratoire d'HCmatologie, HBpital Necker, 149, rue de SBvres, 75730 Paris, France blood and urine concentrations of these four proteins during an experimental nephrotic syndrome in rats, coupled with the study of the changes in the proportion of protein-containing hepatocytes estimated according to an immunocytochemical technique, the peroxidase-antiperoxidase method [(PAP) method] (6).…”

Adaptation of Synthetic Peptide Substrate-Based Assays on a Discrete Analyzer

“…A poor hepatic synthesis of AT III might well account for this decrease. 58 In addition, a DIC process often occurs. 18,79 In 14 cirrhotic patients, we found an immunologic AT III level of 56.5 ± 21.5%, and an AT III activity of 58 ± 22%.…”

Antithrombin III during High-Dose Cytosine Arabinoside Therapy with or without Asparaginase

“…A mild and transient liver toxicity has been reported in 75% of patients who underwent HIDARAC therapy [6,7], Moreover, liver toxicity oc curs very frequently during ASNase administration [8]; coagulation abnormalities are also frequent [8][9][10], and antithrombin III (AT III) levels are dra matically lowered [9][10][11][12], so that an increased risk of thromboembolism has been noticed [11][12][13]. ASNaseinduced depression in AT III appears to be secondary to a reduced production by the liver, where AT III is synthesized [14]. In this study, we have monitored AT III activity and concentration as well as some para meters of liver functionality in patients who received HIDARAC therapy with or without sequential AS Nase administration, in order to evaluate the liver toxicity and/or a possible increased thrombosis risk due to an impaired synthesis of AT III.…”